Monday, November 16, 2026

Sino Biological Launches 4RISE High-Throughput Wet-Lab Services for AI-Driven Drug Discovery

Sino Biological announced its 4RISE high-throughput wet-lab validation services for AI-designed protein binders. The services feature 3-hour cell-free expression, AI-ready binding data in as little as 3 days, and real-time API access to structured target-binding data.

Technical Capabilities and High-Throughput Expression

Sino Biological says its XPressMAX Cell-Free Protein Synthesis (CFPS) platform enables recombinant protein synthesis in 3 hours, with expression success rates exceeding 99% in established workflows. The platform supports the synthesis of miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, accelerating experimental testing of AI-designed protein candidates. Combined with CFPS, the workflow delivers sequence-to-AI-ready binding data in 3 days, and structured binding data are accessible in real time via API for downstream research and analysis.

Screening Workflows and Assay Options

According to Sino Biological’s launch announcement, 4RISE delivers high-throughput binding screening, kinetic analysis, and affinity determination for candidate protein using Carterra high-throughput SPR, Biacore SPR, and Octet BLI. Rapid Hit Discovery identifies binding-positive miniproteins and VHHs through crude-supernatant screening, while Comparative Binder Screening evaluates purified candidates under standardized conditions to support candidate prioritization.

Affinity and Kinetic Characterization provides quantitative binding insights for lead selection, and Specialized Binder Expression and Validation supports diverse binder formats through tailored mammalian expression and binding analysis. Beyond binding, 4RISE provides more than 20 developability assays, 1,000 protein bioactivity assays, and 10 cell-based functional assays, supporting in-depth candidate evaluation and design optimization.

Questions about 4RISE

What collaborative partnerships support 4RISE validation?

Sino Biological says it works with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering, and that 4RISE wet-lab validation has supported studies published in Science, Nature Communications, Scientific Reports, and other high-impact journals. “AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US.

Read More: Fortrea and Omico Partner to Accelerate Global Precision Oncology Research and Trial

spot_img

Subscribe Now

    Hot Topics

    spot_img